AU2021204009B2 — Systems and methods for intelligent gas source management and/or systems and methods for delivery of therapeutic gas and/or enhanced performance verification for therapeutic gas delivery
Assigned to Mallinckrodt Pharmaceuticals Ireland Ltd · Expires 2022-07-21 · 4y expired
What this patent protects
SYSTEMS AND METHODS FOR INTELLIGENT GAS SOURCE MANAGEMENT AND/OR SYSTEMS AND METHODS FOR DELIVERY OF THERAPEUTIC GAS AND/OR ENHANCED PERFORMANCE VERIFICATION FOR THERAPEUTIC GAS DELIVERY ABSTRACT An electronically controlled gas blending device, comprising: a flow control ch…
USPTO Abstract
SYSTEMS AND METHODS FOR INTELLIGENT GAS SOURCE MANAGEMENT AND/OR SYSTEMS AND METHODS FOR DELIVERY OF THERAPEUTIC GAS AND/OR ENHANCED PERFORMANCE VERIFICATION FOR THERAPEUTIC GAS DELIVERY ABSTRACT An electronically controlled gas blending device, comprising: a flow control channel in fluid communication with a therapeutic gas supply, wherein the flow control channel comprises: at least one secondary subsystem flow control valve, wherein the at least one secondary subsystem flow control valve is configured to be in communication over a communication path with a therapeutic gas delivery system controller; and two or more secondary subsystem flow sensors, wherein the two or more secondary subsystem flow sensors are in fluid communication with the at least one secondary subsystem flow control valve, and the two or more secondary subsystem flow sensors are configured to be in communication over a communication path with the therapeutic gas delivery system controller; one or more inlets configured to connect to a gas supply; one or more inlet flow sensors in fluid communication with at least one of the one or more inlets; a blending junction in fluid communication with the one or more inlet flow sensors, and the blending junction is connected to and in fluid communication with the flow control channel; and a therapeutic gas delivery system controller configured to be in electrical communication with at least one of the at least one secondary subsystem flow control valves and the two or more secondary subsystem flow sensors to form a feedback loop, and configured to receive a flow value from the one or more inlet flow sensors and calculate a flow rate of the therapeutic gas through the at least one secondary subsystem flow sensor to provide an intended dose of the therapeutic gas exiting the blending junction, wherein the two or more secondary subsystem flow sensors are arranged in parallel along the flow control channel.
Drugs covered by this patent
- Inomax (NITRIC OXIDE) · Vero Biotech Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.